Browsing Tag
EPCORE FL-1 trial
1 post
Can Epcoritamab plus R2 become the new second-line standard in follicular lymphoma after Genmab’s Phase 3 success?
Genmab’s Epcoritamab plus R2 combo cut FL relapse risk by 79% in Phase 3. Find out why this bispecific therapy may reshape second-line treatment.